ProfileGDS5678 / 1422758_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 69% 70% 77% 70% 68% 69% 66% 69% 69% 72% 69% 69% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.5102172
GSM967853U87-EV human glioblastoma xenograft - Control 24.3091369
GSM967854U87-EV human glioblastoma xenograft - Control 34.3516870
GSM967855U87-EV human glioblastoma xenograft - Control 45.4323777
GSM967856U87-EV human glioblastoma xenograft - Control 54.3292270
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1882968
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.280869
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0243266
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.2849569
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.2918669
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.5604372
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.2751569
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.2546969
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.2584769